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ANALYSIS
The effectiveness of antenatal corticosteroids to pre-
vent neonatal lung disease in women at risk of pre-
term birth was established by systematic reviews. In 
addition, subgroup analyses suggested that treatment 
was most effective in babies born one to seven days 
after administration. This belief led to widespread use 
of repeated courses of corticosteroids in women who 
did not deliver within a week or two of initial treat-
ment. However, the notion that effectiveness declines 
after seven days may be incorrect, as the analyses 
that it is based on are unreliable. Here, we discuss the 
methodological problems of these analyses and their 
relevance to current randomised controlled trials of 
repeated versus single courses.
So, what is the evidence?
Babies born before 32 weeks’ gestation often have 
neonatal lung disease, a major cause of neonatal mor-
tality and morbidity—the earlier the birth, the greater 
the risk. Corticosteroids given to mothers at risk of 
preterm delivery accelerate fetal lung development, 
and the effectiveness of this treatment for preventing 
neonatal lung disease was investigated in a series of 
randomised controlled trials from the 1970s onwards. 
Some trials showed a significant benefit of antenatal 
corticosteroids, but some showed no significant effect. 
A landmark systematic review1- 3 resolved the appar-
ent discrepancies in the results and established that 
this treatment reduced death and respiratory distress 
syndrome in the babies of these women. A forest plot 
from this review is used in the Cochrane Collabora-
tion’s logo, and the intervention is now used routinely 
in clinical practice.
Another clinically important question is whether 
(and how) the effectiveness of antenatal corticosteroids 
changes with time after administration. This question 
was investigated by a subgroup analysis in the first 
randomised controlled trial conducted.4 Women were 
divided into subgroups on the basis of the interval 
between treatment and delivery—less than 24 hours, 
24-48 hours, two to seven days, and more than seven 
days. Respiratory distress syndrome was significantly 
reduced only in babies born two to seven days after 
the first dose of corticosteroids. The somewhat incon-
sistent conclusion was that steroids should be given 
at least 24 hours before delivery to have a noticeable 
effect on lung function,4 and that effectiveness does 
not persist for more than a week.5 This conclusion 
appears to be consistent with the results of laboratory 
studies,6 although corticosteroids act in several differ-
ent ways, and how they affect growth and develop-
ment of the lungs is not certain.7 Subsequent trials and 
four systematic reviews1-3 8 found similar results—a 
large and statistically significant reduction in respira-
tory distress syndrome in the subgroup given corti-
costeroids one to seven days before delivery and a 
smaller (usually non-significant) effect in the other 
subgroups (table). This evidence led, in the 1990s, 
to a widespread practice of repeating treatment in 
women who did not deliver within seven to 10 days 
of receiving it.9 10 Courses were often repeated weekly 
until 34 weeks’ gestation, resulting in prolonged expo-
sure of babies to corticosteroids. More recently, use 
of multiple courses has declined, because of worries 
about adverse effects of exposure to corticosteroids, 
especially in the developing brain. At least nine 
randomised controlled trials have been initiated to 
determine the efficacy and safety of repeated courses. 
The studies reported so far have shown no conclusive 
evidence of short term benefit for repeated courses, 
but long term follow-up is needed to assess the neu-
rodevelopmental effects of this treatment and fully 
understand its risks and benefits.11-13
PRACTICE, p 96
Simon Gates 
principal research fellow, Warwick 
Medical School Clinical Trials Unit, 
University of Warwick, Coventry 
CV4 7AL
Peter Brocklehurst 
director, National Perinatal 
Epidemiology Unit, University of 
Oxford, Oxford OX3 7LF
Correspondence to: S Gates 
s.gates@warwick.ac.uk
Decline in effectiveness of antenatal 
corticosteroids with time to birth: real or 
artefact?
The widely accepted notion that the benefits of antenatal corticosteroids decline with time to 
birth may not be correct, argue Simon Gates and Peter Brocklehurst, as the evidence is based 
on unsound subgroup analyses 
Meta-analyses of trials of corticosteroid treatment for preventing neonatal respiratory distress 
syndrome in women at risk of preterm delivery
Meta-analysis Time period subgroup No of trials
Intervention group
Odds ratio (95% 
confidence interval)Treatment* Control*
Crowley 19891 <24 h 10 61/283 84/297 0.72 (0.49 to 1.06)
24 h to 7 days 12 68/761 155/718 0.31 (0.23 to 0.42)
>7 days 6 27/365 36/372 0.62 (0.35 to 1.08)
Crowley 19902 24 h to 7 days Not stated Not stated Not stated 0.31 (0.23 to 0.42)
<24 h or >7 days Not stated Not stated Not stated 0.69 (0.50 to 0.94)
Crowley 19953 <24 h 12 78/383 99/397 0.80 (0.56 to 1.15)
24 h to 7 days 13 87/855 185/812 0.35 (0.26 to 0.46)
>7 days 7 32/379 41/384 0.63 (0.38 to 1.07)
Roberts and <24 h 9 68/260 74/257 0.82 (0.55 to 1.22)
Dalziel 20068 24 h to 7 days 9 57/563 126/547 0.36 (0.25 to 0.51)
>7 days 8 32/498 37/490 0.80 (0.48 to 1.33)
*Number of events/number of babies.
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What are the problems?
Although the notion of an optimal period of adminis-
tration persists,14 15 certain features of the analyses on 
which this conclusion is based could make them unre-
liable and the conclusion unsound. We describe four 
ways in which misleading results could have arisen.
Arbitrary choice of time period subgroups
The choice of 24 hours and seven days as the cut-off 
points for determining the subgroups was totally arbi-
trary. These time points were used by the first trial to 
be published and have been followed by others, but the 
reasons for choosing them are not clear. They may have 
been chosen to maximise the difference between the 
subgroups, and different cut-off points might have pro-
duced different results. If a period of maximum effec-
tiveness does exist, it may not be a plateau between 
days one and seven.
Babies born at term were all in one subgroup
Most trials recruited women with a gestational age of 
less than 36 weeks. Almost all babies born at term (>37 
weeks) were therefore in the subgroup of babies deliv-
ered more than seven days after randomisation. Death 
and respiratory distress syndrome are rare in babies 
delivered at term; fewer outcomes would therefore 
occur in this subgroup, so a statistically significant differ-
ence would be less likely to be found. Hence, the lack of 
evidence of a difference in this group may simply reflect 
the much lower incidence of outcomes in babies born 
at term. The overall incidence of respiratory distress 
syndrome in the three subgroups in the most recent 
review8 is consistent with this argument—27.5% in the 
less than 24 hours subgroup, 16.4% for one to seven 
days, and 7.0% for more than seven days.
Subgroup comparisons did not use interaction tests
Subgroups with fewer trials or fewer events have greater 
uncertainty and are less likely to give statistically sig-
nificant results than those with more trials or events, 
even if their treatment effects are exactly the same. 
Hence, using statistical significance to assess differences 
between subgroups is unreliable. Instead, statistical tests 
of interaction should always be used to assess subgroup 
differences, both in trials and systematic reviews.16
The time to delivery subgroups contained different 
sets of trials, which complicates the performance of 
interaction tests in these reviews. It would be expected 
that some women would deliver in each time period 
after randomisation in almost all trials, so that data 
should be available for each subgroup for each trial. 
However, in the Cochrane review, only five of 11 trials 
reported data for all subgroups.8 This could introduce 
bias. Firstly, one subgroup may, by chance, contain 
 trials with larger treatment effects or more participants, 
making that subgroup more likely to show a signifi-
cant treatment effect. This would give an impression 
of a difference between the subgroups, which would 
not be seen if data from all the trials were included 
in all subgroups. Secondly, a potential reporting bias 
exists—subgroup results may have been reported in the 
original trial papers because they were statistically sig-
nificant, with non-significant subgroup results not being 
reported. Reviews would then tend to contain those 
subgroups that had significant results.
Subgroups were classified by an outcome variable
The time between randomisation and delivery is not 
known at trial entry, as it is not determined until birth. 
Subgroup analyses classified by variables that arise after 
randomisation are known to have a high risk of pro-
ducing misleading results.17 18 Normally, subgroups are 
defined by variables known at randomisation (figure), 
and comparison between the arms of the trial within 
each subgroup is unbiased, because randomisation 
ensures the arms are balanced.
However, if subgroups are defined by variables that 
arise after randomisation (outcome variables), the risk 
of bias is high (figure). Because membership of a sub-
group depends on the presence or absence of an out-
come, there is no way to ensure that the intervention 
and control groups within each subgroup are balanced, 
either in number of participants or baseline characteris-
tics. Moreover, the subgroups may differ in important 
ways, as participants with or without a particular out-
come are likely to be different. For example, women 
Different types of subgroup analysis. When subgroup analysis 
is classified by a variable known at randomisation (top), the 
composition of the intervention group and control group 
in each subgroup is determined by randomisation. When 
subgroup analysis is classified by a variable determined after 
randomisation (bottom), the composition of the two groups is 
determined by the presence or absence of outcome 1
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Subgroup classified before randomisation
Subgroup classified after randomisation
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who deliver more than seven days after randomisa-
tion may differ from others in age, number of previous 
pregnancies, reasons for the risk of preterm birth, ges-
tational age, or other factors. Any differences between 
subgroups in the effectiveness of the intervention may 
therefore be caused by differences in the composition 
of subgroups. None of the antenatal corticosteroid trials 
provided data comparing the baseline characteristics or 
other outcomes of the time to delivery subgroups, so 
the likelihood of bias cannot be assessed.
Whether the effects of antenatal corticosteroids 
change with time to delivery cannot be adequately 
investigated by the existing analyses, but a valid and 
straightforward method of analysis has been sug-
gested.17 This uses standard techniques to determine 
which baseline characteristics, including randomised 
treatment, are related to the interval between randomi-
sation and delivery, followed by standard subgroup 
analyses on any such variables identified. The origi-
nal (individual patient) data from each trial would be 
needed; this would also allow analysis to be based on 
the exact time to birth rather than the arbitrary catego-
ries used so far. Reanalysis of individual patient data 
may help clarify whether the hypothesised association 
is real, and if so, suggest how long the effects of antena-
tal steroids persist.
The way forward
The widely accepted notion that the benefits of ante-
natal steroids decline with time to birth is based on 
analyses with serious methodological problems and 
may not be correct. Largely as a result of these analy-
ses, many women and babies were given multiple 
courses of steroids during the 1990s, and we do not 
know whether this practice was beneficial or harmful. 
Results of the current trials of multiple versus single 
courses should answer this question, but the results 
of long term follow-up will not be available for sev-
eral years. Until then, reanalysis of the data from the 
original trials may help to clarify whether effectiveness 
declines with time to delivery, and if so, over what 
timescale this occurs.
Two of the recently published trials of single versus 
multiple courses have contained subgroup analyses 
classified by outcome variables.12 19 These included 
analyses of subgroups based on gestational age at birth, 
and one trial claimed a significant benefit of multiple 
courses in babies born at less than 28 weeks. This may 
be misleading. Such analyses should be omitted from 
the reports of other trials and systematic reviews of 
multiple versus single courses or we risk repeating the 
errors made in the conclusions of subgroup analysis of 
the original antenatal steroid trials.
Thanks to Doug Altman and Finbar O’Callaghan for helpful comments on an 
earlier draft.
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SummARY PoINTS
Subgroup analyses in trials and systematic reviews of antenatal corticosteroids for neonatal 
lung disease suggested that effectiveness peaked one to seven days after treatment
This led to repeated treatment courses for women who did not deliver within a week
Methodological problems in these analyses mean that this conclusion may be wrong
Problems included not using interaction tests and classifying subgroups by variables 
arising after randomisation (outcome variables)
Awareness of such problems is low—two recent trials of repeated versus single courses of 
antenatal corticosteroids included analyses of subgroups classified by outcome variables
